Loading…
← CockpitCompetitor Analysis › 4547.T Kissei Pharmaceutical Co., Ltd.Open in the cockpit ↗

Kissei Pharmaceutical Co., Ltd.4547.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.

≈ A small/mid Japanese pharma, like a smaller Ono PharmaceuticalMomentum leader 83
Mkt cap
$1.14B
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$3.03M
20-day average traded
Fwd P/E
14.5×
forward earnings
ROIC−WACC
-2.8 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
76 days
2 Feb 2027
Close · JPY¥4,455
1D+1.2%
1W+18.2%
1M+17.7%
3M+7.0%
6M+3.5%
YTD-4.2%
1Y+11.4%
ATR %2.8%
52w lowhigh11.6% off high

What Kissei Pharmaceutical does

Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.

Sells prescription drugs in Japan through its own sales reps, with a mature urology treatment, silodosin, also licensed to overseas partners that pay royalties. It also in-licenses drugs for Japan from other companies rather than relying only on its own research.

In one line: A small/mid Japanese pharma, like a smaller Ono Pharmaceutical.

Products and services

  • Urology drugs
  • Diabetes drugs
  • Rare disease drugs

Customers

  • Hospitals/specialists prescribing its drugs
  • Patients

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Urology, diabetes and rare disease drug…

What could go right

  • New drug approvals/licensing deals

What could go wrong

  • Clinical trial failure risk
  • Patent cliffs

Moat: narrow (IP / patents). Patent-protected niche drugs, but a smaller pipeline than major domestic pharma peers.

Headquarters: Matsumoto, Japan · Founded: 1946 · Employees: 1,786

Named competitors

Kissei Pharmaceutical at a glance

Size Kissei Pharmaceutical (4547.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.14B, the 684th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,455 on 18 Nov 2026.

Performance Over six months the shares gained 3.5%, against -11.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 5.9% over the last twelve months (peer median -0.9%); the operating margin is 5.8% (peer median -4.9%).

Valuation It trades at 14.5× forward earnings against a peer median of 20.2× (3rd cheapest of 11).

Capital Return on invested capital runs 2.8 points below its cost of capital (5.0% WACC).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20264547.T 124Peer median 90
Six months, rebased to 100: Kissei Pharmaceutical against the median of its 20 peers (local-currency closes).

Kissei Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥97.1B¥97.4B¥88.3B¥75.6B¥67.5B
Revenue growth—+10%+17%+12%—
Gross profit¥44.8B¥43.0B¥41.0B¥34.4B¥29.7B
EBITDA¥10.4B¥1.72B¥10.6B¥8.27B¥2.97B
Net income¥11.2B¥13.8B¥12.0B¥11.2B¥10.5B
Free cash flown/a-¥6.37B¥2.01B-¥2.88B-¥8.78B
Capital expendituren/a¥5.64B¥8.56B¥3.09B¥7.24B
Total debt¥1.70B¥1.48B¥1.60B¥1.73B¥1.95B

Quarterly statements and history in the cockpit →

Kissei Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%002550CMHC006280000989VIYASH2376906855VETONKTR688443688321PYCMEDCL688062600812OMER30000626164547.T6-month return →1-month return →
Up and to the right = strong over both horizons. Kissei Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×200×400×002550CMHC006280000989VIYASH2376906883214547.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kissei Pharmaceutical is the large dot.

Kissei Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4547.T vs 4528.T vs 4516.T vs 4503.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Kissei Pharmaceutical 4547.T$1.14B+3%+6%6%14.5×n/a
ONO Pharmaceutical 4528.T$7.33B-2%-2%22%15.3×-6.8%
Nippon Shinyaku 4516.T$1.42B-20%+18%18%7.9×-18.1%
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%

How Kissei Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kissei Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4547.TPeer medianRank in peer set
1-month return+17.7%-2.0%2nd highest of 21
6-month return+3.5%-11.7%6th highest of 20
Distance from 52-week high-11.6%-35.1%3rd highest of 21
Revenue growth (TTM)+5.9%-0.9%9th highest of 18
Operating margin5.8%-4.9%8th highest of 19
Forward P/E14.5×20.2×3rd cheapest of 11
ROIC minus cost of capital-2.8 pp-9.3 pp7th highest of 18
EV / EBITDA12.6×14.1×2nd cheapest of 5
Net debt / EBITDA-5.0×-0.3×least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%n/an/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a

Questions

Who are Kissei Pharmaceutical's main competitors?
Named competitors: Ono Pharmaceutical (4528.T), Nippon Shinyaku (4516.T), Astellas Pharma (4503.T). The cockpit's measured peer set (industry) also includes Changzhou Qianhong Bio-Pharma (002550.SZ), Cosmo (CMHC.SW), GC Biopharma (006280.KS), Jiuzhitang (000989.SZ), Symbiotec Pharmalab (SYMBIOTEC.NS), Viyash Scientific (VIYASH.NS).
Is Kissei Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 14.5× against a peer median of 20.2×, 3rd cheapest of 11 in its peer set.
How has Kissei Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +3.5% against -11.7% for the median peer; over one year +11.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.